By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the last 12 months, four AbCellera Biologics Inc. executives and directors added shares on the open market, about $2.7 million in total, and none of them sold.
Biggest single buyer: Thermopylae Holdings Ltd., 10% Owner, with roughly $580,000. Notably, at least one C-suite executive was among the buyers.
On the institutional side, 151 funds reported holding ABCL at the end of Q2 2026, and funds were split between buying and selling. Zooming out by quarter: 4 quarters in a row of net buying by insiders. Insiders bought in 5 of the last 7 full quarters.
Are insiders buying or selling ABCL stock?
In the last 12 months AbCellera Biologics Inc. insiders made open-market purchases worth about $2.7 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in ABCL?
The most recent open-market insider trade in ABCL was filed on 2026-08-24.
How many institutions own ABCL?
151 investment managers reported holding ABCL in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded ABCL?
No congressional trades in ABCL were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).